Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 14/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.40 |
| ▸ | SCN1A | P35498 | 2/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.40 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.40 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25303402 | 0.90 | SCN2A (0.34) | SCN10ASCN2ANPY5RPDE10A | |
| SCHEMBL25260306 | 0.86 | PTGES (0.36) | — | |
| SCHEMBL25260842 | 0.85 | SCN10A (0.43) | SCN10AKCNH2SCN5ASCN1ASCN9A | |
| SCHEMBL30590496 | 0.81 | CSNK1E (0.43) | SCN10AKCNH2SCN5ASCN1ASCN9A | |
| SCHEMBL23497833 | 0.75 | PDE10A (0.44) | PDE10A | |
| SCHEMBL25260388 | 0.74 | PDE9A (0.35) | SCN10ASCN2ANPY5RPDE10A | |
| SCHEMBL23508051 | 0.74 | CDK2 (0.44) | PDE10A | |
| SCHEMBL23508220 | 0.72 | CSNK1E (0.40) | — | |
| SCHEMBL23508152 | 0.72 | EGLN1 (0.34) | — | |
| SCHEMBL30013417 | 0.72 | EGLN1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066370-A1 | BICYCLIC TRIAZINE DERIVATIVES FOR THE TREATMENT OF CANCER | DEUTSCHES KREBSFORSCH (DE) | 2025-02-27 | — | — | US | disclosed |
| EP-4463458-A1 | BICYCLIC TRIAZINE DERIVATIVES FOR THE TREATMENT OF CANCER | Deutsches Krebsforschungszentrum (DE) | 2024-11-20 | — | — | EP | disclosed |
| CN-118541372-A | Bicyclic triazine derivatives for the treatment of cancer | 德国癌症研究中心 | 2024-08-23 | — | — | CN | disclosed |
| WO-2023135057-A1 | BICYCLIC TRIAZINE DERIVATIVES FOR THE TREATMENT OF CANCER | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2023-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066370-A1 | BICYCLIC TRIAZINE DERIVATIVES FOR THE TREATMENT OF CANCER | BRCA1, CCNY, CCND2 | SCN10A 4532/4885KCNH2 1791/4885SCN5A 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.